Cincinnati-based Aerpio Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing novel small molecules and monoclonal antibodies to treat vascular diseases and enhance wound healing. The company was spun out from Akebia Therapeutics to enable faster development of its promising compounds, and it is managed by the same team that led Akebia. Aerpio's product pipeline includes razuprotafib, a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma, as well as ARP-1536 and AKB-4924.